Medical Xpress
According to new research from the NYU Grossman School of Medicine, patients who use GLP-1 receptor agonists before undergoing metabolic and bariatric surgery achieve significantly greater weight loss than with medication alone. The study found patients lost about 8% of their body weight on the drugs before surgery. Total weight loss increased to over 25% for those who had gastric bypass and about 20% for those who had sleeve gastrectomy. Karan R. Chhabra, MD, assistant professor in the Departments of Surgery and Population Health at NYU Grossman School of Medicine, noted the findings show surgery delivers substantial weight loss in this population.
5/05/2026
Communication barriers in pediatric oncology can be overcome with ‘meaningful’ discussions
HemOnc Today
Communication preferences frequently conflict in pediatric oncology, creating challenges for clinicians, patients, and parents. In a new study, Caroline S. Christianson, MD, a fellow in pediatric hematology and oncology at at NYU Langone Health, and her colleagues surveyed stakeholders to identify best practices. The research highlights the importance of direct, individualized conversations and establishing a partnership between parents and oncologists. Dr. Christianson emphasizes that asking about preferences helps align communication with families' fears, priorities, and goals. The study also proposes a 'communication champion' on the care team to help facilitate these crucial discussions over time.
Also reporting was: Healio
5/05/2026
Tirzepatide Tied to Less Mortality and AEs Than Semaglutide
Medscape
A real-world comparative effectiveness study found that tirzepatide was associated with lower all-cause mortality and fewer adverse gastrointestinal events than semaglutide. The study's principal investigator, Aasma Shaukat, MD, MPH, gastroenterologist at NYU Langone, the Robert M. and Mary H. Glickman Professor of Medicine, co-director of Translational Research Education and Careers (TREC), and director of Outcomes Research for Gastroenterology and Hepatology at NYU Grossman School of Medicine, said it was surprising that tirzepatide had fewer adverse events. The research, presented at Digestive Disease Week 2026, analyzed two matched groups of 126,971 patients each. Tirzepatide was linked to significantly lower all-cause mortality and a lower risk for ileus/intestinal obstruction and aspiration pneumonitis.
5/05/2026
New Guideline for Cardiac Ultrasound Artifacts Released by ASE
Imaging Technology News
The American Society of Echocardiography has released a new guideline to help cardiovascular ultrasound professionals better recognize and understand cardiac ultrasound artifacts, aiming to enhance diagnostic accuracy and patient safety. The document offers a structured approach to identifying and managing these artifacts, which can lead to misdiagnoses. The guideline was chaired by Muhamed Saric, MD, PhD, clinical director of Non-Invasive Cardiology and professor of medicine in the Leon H. Charney Division of Cardiology at NYU Grossman School of Medicine, who emphasized its importance in reducing diagnostic errors for critical conditions.
5/05/2026
American College of Obstetrics and Gynecology Annual Clinical and Scientific Meeting
Healio Women’s Health & OB/GYN
GLP-1 receptor agonists are not likely to decrease the effectiveness of oral contraceptives, according to research presented at the American College of Obstetrics and Gynecology Annual Clinical and Scientific Meeting. Casey Moffitt, MD, a resident physician in Obstetrics and Gynecology at NYU Langone Hospital—Long Island, who led the study, advised that contraceptive counseling should be incorporated when prescribing these therapies. While data for semaglutide and liraglutide are reassuring, other drugs like tirzepatide can reduce progestin concentration. For tirzepatide, non-oral contraception or a backup method is recommended for four weeks after initiation and each dose escalation.
5/05/2026
Science gets closer to understanding how a psychedelic trip changes the brain
NBC News
A small study in Nature Communications suggests a single psilocybin trip may cause physical brain changes that could explain its psychological benefits. Researchers found that stronger psychedelic experiences correlated with greater therapeutic responses and structural changes in the brain. Commenting on the findings, Joshua Siegel, MD, PhD, psychiatrist and assistant professor in the Department of Psychiatry at NYU Grossman School of Medicine, said there is likely an important relationship between altered consciousness and changing thought patterns. Siegel, also an investigator at the NYU Center for Psychedelic Medicine, noted that while rodent studies show psychedelics increase synapses, the implications for humans remain a key question.
Also reporting was: MSN Deutschland, Yahoo, Aol
5/05/2026
I Love to Strength Train. Do I Really Need Cardio, Too?
The State - NYT News Service/Syndicate Stories
While strength training is popular, experts emphasize the necessity of aerobic exercise for longevity. Julia Iafrate, DO, a sports medicine physician at NYU Langone Health, and clinical assistant professor at the Departments of Orthopedic Surgery and Rehabilitation Medicine at NYU Grossman School of Medicine, observed a 'pendulum swing' toward muscle-building workouts, partly due to their time efficiency and visible results. However, she highlighted that combining strength training with cardio reduces the risk of death from any cause by at least 40%. The article also includes commentary from experts at Northwell Health and the Hospital for Special Surgery, who agree that cardio is crucial for cardiovascular health.
Also reporting was: The Bellingham Herald, The Sun News, The Sacramento Bee, Fort Worth Star-Telegram, Columbus Ledger-Enquirer, Centre Daily Times, The Charlotte Observer, Tacoma News Tribune, The Telegraph (Macon), Bradenton Herald, San Luis Obispo Tribune, Belleville News-Democrat, Tri-City Herald, Wichita Eagle, The Island Packet, Lexington Herald-Leader, Rock Hill Herald, Merced Sun-Star, Idaho Statesman, The Modesto Bee
5/05/2026
What To Know About the New GLP-1 Pills
Katie Couric Media
In an opinion piece, Melanie R. Jay, MD, professor of medicine and population health at NYU Grossman School of Medicine, and director of the NYU Langone Comprehensive Program on Obesity Research, discusses new oral GLP-1 medications for obesity. She explains that while pills like semaglutide and orforglipron increase accessibility compared to injectables, they carry risks. These include potential misuse for cosmetic weight loss, the need for ongoing medical support to manage side effects and prevent muscle loss, and navigating a market of unregulated products. Jay stresses that these are powerful drugs for a chronic disease and should be part of a long-term, health-focused treatment plan.
Also reporting was: Yahoo Health
5/05/2026
